| Patient | Ella Fitzgerald |
|---|---|
| Date of birth | 1956-04-25 |
| Identifiers | MRN HR-ML029-SYN; SSN (made up) 000-29-3640 |
| Document date | 2026-06-15 |
| Author | Odessa Whitlow, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Subsequent annual wellness visit. [S]
Ms. Fitzgerald is a 70-year-old singer with type 2 diabetes and peripheral artery disease, macular edema in the right eye, and coronary bypass surgery last year, who comes for her subsequent annual wellness visit five weeks after her first visit and three weeks after her vascular surgery consultation. Since glipizide was stopped and glargine was moved to the morning, her continuous glucose monitor has shown one reading of 66 mg/dL, on a travel day when lunch was late, and none below 54. She started low-dose rivaroxaban with her aspirin after the consultation and has had no bleeding. She has had two weeks of the supervised walking program and can already walk a little farther. She had her first injection in the right eye two weeks ago and saw the podiatrist last week, who pared the calluses and measured her for low-heeled stage shoes. She has a two-week run of concerts starting next month. [S]
| Element | Detail |
|---|---|
| Visit | Subsequent annual wellness visit |
| Glucose | One reading of 66 mg/dL on a travel day; none below 54 mg/dL |
| New since intake | Empagliflozin, glargine in the morning, rivaroxaban 2.5 mg twice daily, continuous glucose monitor |
| Walking program | Supervised exercise three times a week for two weeks |
| Eye and foot care | First right-eye injection two weeks ago; podiatry last week |
| Functional status | Independent; walks about two blocks; uses a wheelchair in large airports |
Health risk assessment. Completed with a medical assistant reading the questions aloud, because of her right-eye vision, and reviewed with her by Dr. Whitlow. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good, and better than last year after the heart surgery |
| Psychosocial | Her music and audiences give her purpose; her band and road manager are close; no loneliness |
| Behavioral | No tobacco; alcohol rarely; meals irregular on tour; walking program three times a week; sleeps about seven hours, later on show nights |
| Activities of daily living | Independent in bathing, dressing, eating, toileting, and transfers |
| Instrumental activities of daily living | Manages her medicines with a weekly organizer; her road manager handles travel; does not drive |
| Home safety | Smoke detectors working; rugs secured; good lighting; no firearm |
| Falls | No falls in the past year; careful on stage steps |
| Hearing and vision | No hearing concern; right-eye vision blurred, under treatment; lens implants in both eyes |
| Bladder | No incontinence; urinates a little more since empagliflozin |
| Memory | No concerns; learns new songs easily |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight down 0.6 kg; no fever or fatigue |
| Eyes | Positive | Right-eye blur, slightly better since the injection; no eye pain or redness |
| Ears, nose, mouth, and throat | Negative | No hearing change; voice strong |
| Cardiovascular | Positive | Calf cramping after about two blocks; no chest pain, breathlessness, palpitations, or ankle swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | No nausea, diarrhea, or blood in the stool |
| Genitourinary | Negative | No burning, itching, or discharge on empagliflozin |
| Musculoskeletal | Negative | No joint pain limiting walking |
| Integumentary | Negative | No foot sores or blisters on daily checks |
| Neurological | Negative | No numbness, tingling, or weakness |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
| Endocrine | Negative | No shakiness or sweating since the plan changed, apart from one mild low on a travel day |
| Hematologic | Negative | No bruising, nosebleeds, or bleeding gums on rivaroxaban and aspirin |
13 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals | One tablet by mouth twice daily with breakfast and the evening meal | Oral route | 2016-03-01 | active | S |
| Glipizide 10 mg oral tablet, one tablet by mouth twice daily before meals | One tablet by mouth twice daily before breakfast and the evening meal | Oral route | 2021-09-01 to 2026-05-11 | completed | S |
| Insulin glargine 100 units/mL pen, 30 units under the skin at bedtime | 30 units at bedtime | Subcutaneous route | 2023-04-01 to 2026-05-11 | completed | S |
| Insulin glargine 100 units/mL pen, 24 units under the skin each morning | 24 units each morning, at the same clock time on tour, with written time-zone adjustments | Subcutaneous route | 2026-05-11 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2025-06-02 to 2026-05-11 | completed | S |
| Atorvastatin 80 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-11 | active | S |
| Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2025-06-02 | active | S |
| Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2025-06-02 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning; hold on days she cannot eat or drink normally and before surgery | Oral route | 2026-05-11 | active | S |
| Glucagon 3 mg nasal powder, one spray into one nostril for a severe low glucose | One spray into one nostril if she cannot safely swallow during a low glucose; may repeat once after 15 minutes with a new device; call 911 | Nasal route | 2026-05-11 | active | S |
| Rivaroxaban 2.5 mg oral tablet, one tablet by mouth twice daily with aspirin 81 mg | One tablet by mouth twice daily, with aspirin 81 mg once daily | Oral route | 2026-05-26 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-15 | Body height | 165 | cm | S |
| 2026-06-15 | Body weight | 83.4 | kg | S |
| 2026-06-15 | Body mass index (BMI) [Ratio] | 30.6 | kg/m2 | S |
| 2026-06-15 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-06-15 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-06-15 | Heart rate | 60 | /min | S |
| 2026-06-15 | Respiratory rate | 16 | /min | S |
| 2026-06-15 | Body temperature | 36.6 | Cel | S |
| 2026-06-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-15 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-06-15 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 2026-06-15 | Total score [AUDIT-C] | 1 | {score} | S |
Vital signs recorded on 2026-06-15; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well and animated; weight 83.4 kg, BMI 30.6; blood pressure 124/68 |
| Eyes | Lens implants in both eyes; injection site in the right eye healed; no redness |
| Ears, nose, and throat | Whispered voice heard in both ears |
| Cardiovascular | Regular rhythm; healed sternotomy scar; no murmur; femoral pulses present; right foot pulses absent and left faint, as before |
| Respiratory | Clear to auscultation bilaterally |
| Feet | Calluses pared; hammer toes; skin intact; no ulcer; protective sensation intact |
| Musculoskeletal | Timed Up and Go 11 seconds without an aid |
| Neurological | Oriented; recall and reasoning normal; Mini-Cog 5 of 5 |
| Psychiatric | Euthymic and engaged |
| Skin | No suspicious lesions on the exposed skin |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Type 2 diabetes mellitus with peripheral artery disease: cramping in both calves after about one and a half blocks of walking, worse on the right, easing within minutes of rest; no rest pain, wounds, or color change. Resting ankle-brachial index 0.62 right and 0.74 left, toe-brachial index 0.46 and 0.55; dorsalis pedis and posterior tibial pulses absent on the right and faint on the left. A1c 8.6% on metformin, glipizide and glargine, with low glucose readings (to 52 mg/dL) after late performances. Foot: protective sensation intact to the 10-g monofilament at all sites and to vibration; callus under the second metatarsal heads; hammer toes of the second and third toes; no ulcer (IWGDF risk category 2). Synthetic modern episode linked to her documented diabetes and its circulatory complications | active | confirmed | E11.51 | S — Synthetic modern diagnosis; the type of diabetes was not made public and is synthetic. |
| Moderate nonproliferative diabetic retinopathy with center-involving diabetic macular edema in the right eye (best-corrected acuity 64 letters, about 20/50) and moderate nonproliferative retinopathy without macular edema in the left eye (81 letters); lens implants in both eyes from earlier cataract surgery. Synthetic modern episode linked to her documented diabetic eye problems | active | confirmed | E11.3311 | S — Synthetic modern eye diagnosis on retinal imaging and optical coherence tomography in the clinic; the left eye is described in the display. |
| Coronary artery disease after five-vessel coronary bypass surgery last year, with an intensive care stay; no angina now; on aspirin, a statin, and metoprolol. Synthetic modern episode linked to her documented heart surgery | active | confirmed | I25.10 | S — Synthetic modern coding of her documented heart surgery; bypass grafts are described in the display. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Influenza vaccine | Due | High-dose or adjuvanted vaccine due in the autumn |
| COVID-19 vaccine | Due | Recommended at 65 and older; due in the autumn |
| Pneumococcal vaccine | Completed today | PCV20 given today; no further doses needed |
| Recombinant zoster vaccine | Due | Dose 1 at the autumn review with the influenza vaccine, dose 2 two to six months later |
| RSV vaccine | Due | Recommended at 60 to 74 with diabetes complications and heart disease; one dose before the respiratory season |
| Tetanus, diphtheria, and pertussis | Up to date | Tdap four years ago |
| Breast cancer screening | Ordered | Mammogram every two years to 74; last one two years ago |
| Colorectal cancer screening | Up to date | Normal colonoscopy four years ago; next due at ten years, with the decision individualized after 75 |
| Osteoporosis screening | Ordered | Bone density scan recommended at 65 and older; none on record |
| Hepatitis C screening | Ordered | One-time screening for adults through 79; added to the three-month tests |
| Depression screening | Completed today | PHQ-2 score 0 |
| Alcohol misuse screening | Completed today | AUDIT-C score 1 |
| Cognitive assessment | Completed today | Mini-Cog 5 of 5 |
| Falls prevention | Completed today | Timed Up and Go 11 seconds; no falls; exercise program under way |
| Diabetic eye examination | Up to date | Retina clinic treating the right macular edema; both eyes examined |
| Diabetic foot examination | Completed today | No ulcer; podiatry every three months |
| Kidney screening | Up to date | eGFR 67 and urine albumin-creatinine ratio 18 mg/g at intake |
| Lung cancer and abdominal aortic aneurysm screening | Not indicated | She has never smoked |
Immunizations given today: Pneumococcal conjugate vaccine (PCV20) [S]
Guideline basis: Standards of Care in Diabetes—2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026); Medicare Wellness Visits (Medicare Learning Network) (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); Adult Immunization Schedule by Age (2026)
Follow-up: Mammogram and bone density scan to be scheduled between tour dates. Three-month review in eight weeks with A1c, lipids, kidney tests, and hepatitis C screening. Next annual wellness visit in one year. Next scheduled visit 2026-08-10: three-month review: A1c, lipids, walking program, eye treatment, and foot care. [S]
Voluntary advance care planning discussion of about 18 minutes, with her consent. She reviewed the written directive she made before her heart surgery and confirmed a health care agent, recorded in the confidential part of the chart and not named here. She said that what matters most to her is to keep singing and travelling for as long as she can, and to keep her sight. She will review the directive yearly. [S]